Search

Search Constraints

You searched for: Author/Creator Sholter, D.

Search Results

1. AB0228 Variability in Patient Characteristics and Outcomes in Rheumatoid Arthritis upon Infliximab Treatment Based on the Size of the Biologic Treatment Registry Site. (10th June 2014)

2. AB0234 Differential Relative Contribution of Individual Components on DAS28 over Time. an Analysis from the Prospective, Observational Registry, Biotrac. (10th June 2014)

3. AB0236 What Level of Disease Activity at 6 Months Predicts Achieving or Sustaining Remission at 12 Months?. (10th June 2014)

4. AB0302 Profile of Joint Involvement over Time in Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Anti-TNF in A Real-World Setting. (10th June 2014)

5. AB0761 Prevalence of Enthesitis and Dactylitis, Impact on Disease Severity and Evolution over 12 Months in PSA Patients Treated with Anti-TNF in A Real-World Setting. (10th June 2014)

6. AB1044 Are There Gender Specific Differences in Patient Reported Outcomes at Initiation of Golimumab Treatment in Rheumatoid Arthritis?. (10th June 2014)

7. AB1059 Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in A Canadian Setting. (10th June 2014)

8. FRI0036 What is the Level of Agreement Between Disease Activity Indices and Response Criteria Among Rheumatoid Arthritis Patients Treated with TNF Inhibitors?. (9th June 2015)

9. FRI0204 What is the Correlation of Individual HAQ and Basdai Questions with Disease Activity Measures in Ankylosing Spondylitis? Implications for Instrument Reduction. (9th June 2015)

10. FRI0467 Predictors of Early Minimal Disease Activity in PSA Patients Treated with Anti-TNF in A Real-World Registry. (15th July 2016)